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The antigenic structure of the VP4 protein of human rotavirus (HRV) str.ains Wa and ST3 was studied by using a panel 
of Wa- and ST3-derived VP4-specific neutralizing monoclonal antibodies (NMAbs) and NMAb-resistant variants. The VP4- 
coding genes from three Wa and three ST3 variants were sequenced. For Wa VP4, one homotypic and one heterotypic 
neutralization site, at amino acids 458 and 392, respectively, were identified. For ST3 VP4, three neutralization sites were 
found at amino acids 72, 217, and 385 that are either homotypic or associated wit[q limited cross-reactivity. Cross-neutraliza- 
tion assays using several pairs of NMAbs and resistant variants showed that Wa VP4 has at least one large neutralization 
domain on its larger trypsin cleavage product, VP5*, consisting of several operationally related epitopes. VP4 of ST3 has 
at least two neutralization domains, one located on VP5* that is operationally related to the large neutralization domains 
on VP5* from HRVs Wa and KU, as well as an independent neutralization domain on VP8*, the smaller trypsin cleavage 
product of VP4. © 1995 Academic Press, Inc. 
INTRODUCTION 
Group A rotavirus particles consist of 11 segments of 
double-stranded RNA enclosed in a trilayered protein 
capsid (Estes and Cohen, 1989). The outer capsid shell 
consists of an 86.5-kDa protein, VP4, encoded by ge- 
nome segment 4, and a 37-kDa glycoprotein, VPT, en- 
coded by genome segments 7, 8, or 9 depending on the 
strain (Estes and Cohen, 1989). Both outer capsid pro- 
teins elicit the production of neutralizing antibodies (Offit 
and Blavat, 1986); hence, the serotypic specificity of ro- 
tavirus is dual, and is termed G and P for VP7 and VP4, 
respectively. Oral infection with live rotavirus stimulates 
protective immunity which can be mediated via VP4 or 
VP7 (Hoshino et al., 1988; Offit et al., 1986a). In addition, 
neutralizing monoclonal antibodies (NMAbs) to either 
VP4 or VP7 have been shown to passively protect mice 
against rotavirus challenge (Offit et al., 1986b). 
VP4 forms spikes, probably dimeric, that protrude from 
the smooth viral surface (Prasad et al., 1988; Yeager et 
al., 1990), is the viral hemagglutinin (Kalica et aL, 1983), 
and is cleaved by trypsin into VP8* (amino acids 1-247) 
Sequence data from this article have been deposited with the EMBL/ 
GenBank Data Libraries under Accession Nos. L33895 (strain ST3 gene 
4) and L34161 (strain Wa gene 4). 
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and VP5* (amino acids 248-776) (Espejo et aL, 1981; 
Estes etaL, 1981; L6pez etaL, 1985). Proteolytic cleavage 
strongly enhances rotavirus infectivity, probably by en- 
hancing virus penetration to the cell (Estes et aL, 1981; 
Fukuhara et al., 1988; Kaljot et aL, 1988). 
The VP4 from human rotaviruses (HRVs) has been 
classified into three serotypes and one subtype associ- 
ated with symptomatic infections (P1A, P1 B, P3, and P4), 
and one serotype associated with asymptomatic infec- 
tions (P2), as determined by neutralization assays with 
monospecific antisera (Gorziglia et aL, 1990; Li et al., 
1993, Sereno and Gorziglia, 1994), 
By sequencing escape mutants selected with anti-VP4 
NMAbs, amino acids involved in homologous and heter- 
ologous neutralization have been identified (Taniguchi et 
al., 1988; Mackow etal., 1988). In this study, homologous 
refers to strains bearing the same P serotype, while in 
early studies it referred to G serotypes due to the lack 
of a P serotyping scheme. Most VP4-directed NMAbs 
derived from animal rotaviruses are homotypic or exhibit 
limited heterotypic activity, and induce amino acid 
changes within a large hypervariable region in VP8* 
(amino acids 87-194), while heterotypic NMAbs from 
animal rotaviruses induce amino acid changes in a lim- 
ited area on VP5*, spanning amino acids 388-393 
(Mackow et al., 1988; Zhou et aL, 1994). NMAbs derived 
from human rotaviruses are mostly heterotypic and in- 
duce amino acid changes in the region of VP5* spanned 
by amino acids 305-441 (Kobayashi et aL, 1990; Tani- 
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guchi eta/., 1988). The amino acids important for neutral- 
ization by homotypic anti-VPS* NMAbs derived from hu- 
man rotaviruses have not been identified (Kitaoka et al., 
1986; Padilla-Noriega eta/., 1993). 
The topography of neutralization epitopes on VP4 of 
animal and human rotaviruses have been studied by ex- 
amining the reactivity patterns of NMAbs against neutral- 
ization escape viral variants, and by competitive NMAb 
binding. According to the former method, which in this 
study is referred to as viral variant analysis, the epitopes 
recognized by two NMAbs are considered operationally 
overlapping if a viral variant selected with either NMAb 
acquires resistance to the second NMAb. A particular 
set of operationally overlapping epitopes is considered 
a domain (Yewdell and Gerhard, 1981). Using the animal 
rotavirus train RRV, Shaw et aL, (1986) identified three 
separate neutralization domains by viral variant analysis, 
two homotypic domains on VPS* and one heterotypic 
domain on VP5*, the former two being indistinguishable 
by competitive binding analysis. Using the HRV strain 
KU, Taniguchi eta/. (1987)identified on VP5* two neutral- 
ization domains by viral variant analysis. One of these 
domains is recognized solely by NMAb YO-2C2, which 
induced an amino acid change at position 305, and the 
second seems to be a larger domain recognized by 11 
NMAbs that induced amino acid changes at positions 
385, 392, 428, or 433 (Kobayashi et al., 1990). The anti- 
genic topography of neutralization epitopes on VPS* of 
HRVs has not been studied. 
We recently described anti-VP4 NMAbs directed to the 
VP4 protein of HRV strains Wa (serotype P1A) and ST3 
(serotype P2) that are homotypic, heterotypic, or exhibit 
limited cross-reactivity (Padilla-Noriega et a/., 1993). Pre- 
liminary analysis of these NMAbs indicated that at least 
one is VPS*-specific. To further characterize the antigenic 
structure of the VP4 protein of HRVs, we selected Wa 
and ST3 rotavirus variants resistant to neutralization by 
these NMAbs and identified the mutations that allow the 
viruses to escape neutralization. The escape variants 
were also studied by viral variant analysis in order to 
gain knowledge on the topography of neutralization epi- 
topes on the VP4 protein on HRV strains. 
MATERIALS AND METHODS 
Viruses 
The two HRV strains used in this work were from 
stocks in the laboratory of one of the authors (H.B.G.). 
Strain Wa (serotype G1, P1A) was originally obtained 
from R. G. Wyatt (National Institutes of Health, Bethesda, 
MD). Strain ST3 (serotype G4, P1A) was originally ob- 
tained from R. L. Ward (James N. Gamble Institute of 
Medical Research, Cincinnati, OH), who had in turn ob- 
tained it from R. G. Wyatt. Prior to the selection of the 
viral variants, the two HRV strains were triply plaque 
purified and named as clone 1 afterwards. Strain ST3 
had been previously plaque purified thrice by R. L. Ward. 
Monoclonal antibodies 
The production and partial characterization of the nine 
anti-VP4 NMAbs used in this study were described pre- 
viously (Padilla-Noriega et al., 1993). Five NMAbs were 
derived from the HRV Wa (1A10, 1C6, 1E4, 2Cll ,  and 
2A3), and four NMAbs from the HRV ST3 (HS6, HS7, 
HS11, and HS16). 
Selection of neutralization escape variants 
Five Wa variants (Wa-lA10, Wa-IC6, Wa-IE4, Wa- 
2Cll ,  and Wa-2A3) were selected with five Wa-derived 
NMAbs, and four ST3 variants (ST3-HS6, ST3-HS7, ST3- 
HS11, and ST3-HS16) were selected with four ST3-de- 
rived NMAbs: Each variant was designated with the 
name of the parental strain followed by the NMAb used 
for its selection. The variants were selected and plaque 
purified as described elsewhere (Taniguchi eta/., 1987). 
PCR amplification and sequencing of gene 4 of 
rotaviruses 
Viral dsRNA was purified, reverse-transcribed, PCR- 
amplified, and sequenced as previously described (Dunn 
et al., 1993). PCR amplification of ST3 gene 4 was done 
with the 5' and 3' primers GGCTATAAAATGGCTTCACT- 
CAAT and GGTCACATCCACTATAGAGCTCTC, respec- 
tively. PCR amplification of Wa gene 4 was done with 5' 
and 3' primers GAATTCGGATCCGGCTATAAAATGGCT 
and GGTCACATCCTGGATGACA-rTCTG, respectively. 
Focus reduction neutralization assay 
Neutralization titers of NMAbs were determined as 
described by Shaw et aL (1985). 
Determination of the protein specificity of the NMAbs 
The specificities of the N MAbs to the ST3 VP4 polypep- 
tides VPS* and VP5* were determined by DNA amplifica- 
tion-restricted transcription translation (DARTT) (Mackow 
eta/., 1990), with some modifications. Briefly, full-length 
ST3 gene 4 cDNA was PCR-amplified as indicated above 
and phenol-chloroform-extracted, Ethanol-precipitated 
gene 4 cDNA was used as a template for subsequent 
PCRs of VP8* and VP5* in the presence of 5'-end oligonu- 
cleotides containing a T7 polymerase promoter se- 
quence. The 5' and 3' primers used to amplify VP8* 
sequences encoding amino acids 1-246 were GAATAA- 
TAC GACTCACTATAG G GATG G CTTCACT-  
CATTTATAGA and ACGTTGATAAGTCACTGATCTAGA, 
respectively. VP5* encoding sequences (amino acids 
247-775) were amplified using the 5' oligonucleotide 
GAATAATAC GACTCACTATAG G GATG G CTCAG G TTAG- 
TGAAGATATC and the same 3' oligonucleotide used for 
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TABLE 1 
AMINO ACID DIFFERENCES BETWEEN THE VP4s OF DIFFERENT CLONES OF HRV STRAINS Wa AND ST3 
HRV strain Amino acid difference (residue number) ~ 
Wa 
ST3 
lie-Met (64) Ser-Phe (331) Leu-Ile (388) Gly-Asp (525) 
Thr-Val (49) Trp-Leu (50) Ser-Glu (51) His-Ser (52) 
Gly-Trp (53) Arg-GIn (70) Ile-Val (130) Asn-Ser (146) 
Thr-Ser (175) Ser-Asn (250) Pro-Ala (313) Ser-Leu (331) 
Ile-Val (338) Asp-Asn (353) Met-lie (388) GIn-Lys (413) 
Leu-Pro (474) Gly-Arg (565) VaI-Glu (589) Asp-lie (633) 
The first amino acid of each pair corresponds to the VP4 sequences determined by us and the second to the published sequences of Wa VP4 
(Kitamoto et aL, 1993) or ST3 VP4 (Gorziglia et aL, 1988). 
full-length gene 4 amplification. PCR-amplified VP8* and 
VP5* sequences were transcribed by T7 RNA polymer- 
ase and translated in the presence of [35S]methionine, as 
previously described (LOpez et aL, 1994). The translated 
proteins were immunoprecipitated with NMAbs from as- 
cites essentially as described by Mackow et al. (1990), 
except that reactions were performed at 4 ° , and in the 
presence of two additional protease inhibitors, 0.3 #M 
aprotinin (Boehringer) and 1 #M leupeptin (Boehringer). 
Two ST3-derived MAbs that had been previously shown 
to be reactive with Wa VP8* (MAb HS6) or VP5* (MAb 
HS2) by the DARq-I-technique (Padilla-Noriega etaL, 1993) 
were used as positive controls for radioimmunoprecipita- 
tions. Normal ascites produced from a mouse inoculated 
intraperitoneally with the nonsecreting myeloma cell line 
FOX was used as negative antibody control. 
RESULTS 
Amino acid sequence of VP4 from the parental 
strains Wa and ST3 
The sequence of Wa gene 4 found in this study differs 
from that found by Kitamoto et al. (1993; GenBank Acces- 
sion No. M96825) by five nucleotides that result in 4 
amino acid changes (Table 1). In addition, our sequence 
of Wa gene 4 has two extra thymidines in the 3' noncod- 
ing region, aft.er nucleotide 2345 of the published se- 
quence. The amino acid sequence of ST3 gene 4 found 
here differs from that of Gorziglia et al. (1988) by 20 amino 
acids (Table 1). It is unclear why there are numerous 
amino acid differences beween the two ST3 VP4s com- 
pared. Since our ST3 strain was extensively cloned (see 
Materials and Methods), one possible explanation for 
these differences is that we selected minor viral variants. 
A comparative analysis of the amino acid differences 
between the VP4 proteins of HRVs Wa and ST3 has been 
reported (Gorziglia et aL, 1988). 
Identif ication of amino acid changes of Wa and ST3 
variants selected with anti-VP4 neutral izing 
monoclonal  ant ibodies 
In order to localize the neutralization epitopes recog- 
nized by anti-VP4 NMAbs and to construct an operational 
antigenic map of the VP4 protein of HRV strains Wa and 
TABLE 2 
NUCLEOTIDE AND PREDICTED AMINO ACiD CHANGES OF Wa AND ST3 VARIANTS SELECTED WITH ANT~-VP4 NMAbS, AND PROTEIN-BINDING 
AND VP4 SEROTYPE SPECIFICiTIES OF THE SELECTING NMAbs 
Variant Amino acid Protein-binding VP4 serotype specificity 
virus ~ Codon (bp number) (residue number) specificity b of selecting NMAb 
ST3-HS6 ACA ~ ATA (224) Thr ~ lie (72) VP8* P2-P1A ° 
ST3-HSl 1 GAA ~ AAA (658) Glu ~ Lys (217) VPS* P2 
ST3-HS16 AAT ~ GAT (1162) Ash ~ Glu (385) VP5* P2 
Wa-1 E4 GCA ~ GTA (1184) Ala ~ Val (392) NP P2-P1A 
Wa-IA10 GGA ~ AGA (1378) Gly ~ Arg (458) VPS* P1A 
Wa-lC6 GGA ~ AGA (1378) Gly ~ Arg (458) VP5* P1A 
ST3-HS7 N D '~ N D VP5* P2- P1A 
Wa-2C11 ND ND VP5* P2-P1A 
Wa-2A3 ND ND VP5* P2-P1A 
8 Variants were designated with the name of the parental strain followed by the NMAb used for its selection. 
b The protein specificity was determined by in vitro transcription of the VP5* or VP8* region of ST3 (this study) or Wa (Padilla-Noriega et aL, 1993) 
gene 4 cDNA followed by translation and radioimmunoprecipitation by MAbs from ascitic fluid. NP, nonprecipitating. 
° NMAb HS6 exhibits limited cross-reactivity since it neutralizes erotype P2 strains and one of five serotype P1A strains tested (Padilla-Noriega 
et aL, 1993). 
d ND, not determined. 
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KDa MW VP8* VPS* 
1 r2  3 4 51 '6  7 8 9 10' 
97 - " 
vPs*e~ 0 
46-  W 
21- O 
FIe. 1. Radioimmunoprecipitation of in vitro translated VP8* or VP5* 
by NMAbs. Selected regions (VP5* or VP8*) of ST3 gene 4 cDNA were 
amplified by PCR with simultaneous addition of T7 polymerase tran- 
scription signals and transcribed into RNA by T7 RNA polymerase. The 
mRNA produced was translated in a rabbit retyculocyte lysate system 
with [358]methionine. The translated VP8* (lane 2) or VPS* (lane 6) was 
immunoprecipitated with NMAbs and analyzed by 10% PAGE. Lane 1 
contains molecular weight markers. The NMAbs tested against VP8* 
were MS6 (lane 3), HSl 6 (lane 4), and HS11 (lane 5). The NMAbs tested 
against VPS* were HS2 (lane 7), HSl 6 (lane 8), and HS11 (lane 9). Lane 
10 is a negative control of normal ascites tested against VPS*. HS2 is 
an ST3-derived MAb previously shown to be reactive with Wa VP5*. 
ST3, five Wa variants were selected with Wa-derived 
NMAbs, and four ST3 variants were selected with ST3- 
derived NMAbs. The VP4 serotype specif icity of the se- 
lecting NMAbs had been previously determined (Table 
2)(Padilla-Noriega et aL, 1993). Two N MAbs are serotype 
P1A-specific (1A10 and 106) and two are serotype P2- 
specific (HS11 and HS16). Four are heterotypic since 
they neutralize both serotype P1A and P2 strains (1E4, 
HS7, 2011, and 2A3). One NMAb exhibits l imited cross- 
reactivity (HS6) since it neutral izes serotype P2 strains 
and one of five serotype P1A HRV strains tested. Variants 
were des ignated with the name of the parental strain 
fo l lowed by the NMAb used for its selection. 
The gene 4 sequence from three ST3 and three Wa 
variants was  determined.  Table 2 shows the nucteotide 
changes and the corresponding amino acid substitutions 
in the six variants. Both Wa variants selected with sero- 
type P1A-specific NMAbs 1A10 and 106 sustained the 
same amino acid change in VP5*, at position 458. The 
ST3 variants selected with serotype P2-specific NMAbs 
sustained amino acid changes at posit ions 386 in VP5* 
(ST3-HS16) or 217 in VP8* (ST3-HSl 1). The ST3 variant 
selected with the moderately heterotypic NMAb HS6 sus- 
tained an amino acid change in VP8* at posit ion 72 (ST3- 
HS6). The Wa variant selected with a heterotypic NMAb 
sustained an amino acid change at posit ion 392 in VP5* 
(Wa-1 E4). Tv~o of the five amino acid substitutions found, 
at posit ions 385 and 392 (Table 2), had been previously 
-identified in KU variants selected with a homotypic and 
several heterotypic NMAbs, respectively (Kobayashi et 
aL, 1990; Taniguchi  et al., 1988). 
Binding of NMAbs  to the VP4 trypsin c leavage 
products  VP5* or VP8* 
We had previously determined the specif icity of our 
VP4 NMAbs for binding to either of the trypsin c leavage 
products, VP5* or VP8*, of Wa VP4. Five NMAbs were 
found to immunoprec ip i tate  VPS* (1A10, 106, 2011, 2A3, 
and HS7), one precipitated VP8* (HS6), and three did 
not precipitate either polypept ide (HSl 1, HS16, and 1E4) 
(Padi l la-Noriega et aL, 1993). We extended those results 
by testing whether  the ST3-derived NMAbs that did not 
TABLE 3 
NEUTRALIZATION TITERS OF VP4-SPECIFIC NMAbs AGAINST NEUTRALIZATION ESCAPE VARIANTS AND PARENTAL HUMAN ROTAVIRUS STRAINS Wa AND ST3 
Neutralizing titer of monoclonal ntibody (immunogen) b 
Neutralization Protein specificity of 
escape variant or selecting NMAb 1A10 lC6 1 E4 2011 2A3 YO-IS3 YO-202 HS7 HS16 HS6 HSl 1 
parental virus (mutated amino acid) a (Wa) (Wa} (Wa) (Wa) (Wa) (YO) (YO) (ST3) (ST3) (ST3) (ST3) 
Wa-derived variants 
Wa-lA10 VPS* (458) 
Wa-lC6 VP5* (458) 
Wa-IE4 NP (392). 
Wa-2C11 VP5* (ND) 
Wa-2A3 VPS* (N D) 
Wa (parent virus) 
ST3-derived variants 
ST3-HS7 VP5* (ND) 
ST-HS16 VP5* (385) 
ST3-HS6 VP8* (72) 
ST3-HSl 1 VP8* (217) 
ST3 (parent virus) 
< 1 oo 400 25,600 6,400 6,400 800 />409,600 100 
< 100 400 6,400 6,400 6,400 800 />409,600 1 oo 
6,400 100 100 <100 <100 200 >/409,600 <100 
25,600 1 oo < 1 oo < 1 oo < 1 oo < 200 t>409,600 < 1 oo 
25,600 1,600 <100 <100 <100 <200 NT <100 
25,600 6,400 6,400 1,600 6,400 3,200 />409,600 25,600 
25,600 1,600 400 1,600 >t409,600 1,600 6,400 t ,600 25,600 
800 400 400 />409,600 >/409,600 />409,600 <100 1,600 6,400 
25,600 6,400 25,600 t>409,600 />409,600 I>409,600 />409,600 <1  100 
6,400 6,400 6,400 1>409,600 />409,600 />409,600 102,400 1,600 <100 
25,600 6,400 6,400 I>409,600 ~>409,600 />409,600 />409,600 1,600 25,600 
°NP, nonprecipitating, ND, not determined. 
°Titers are expressed as the reciprocal of the highest dilution that neutralized 60% of the infectious virus. Blank spaces indicate that the 
corresponding homotypic NMAbs were not assayed against the heterotypic rotavirus strains. Boldface indicates that the neutralization titer of the 
NMAb to the variant was at least t6-fold lower than the titer to the parental virus. NT, not tested. 
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Wa ST3 
VP8* 
FIG. 2. Operational map of neutralization epitopes on VP4 trypsin 
cleavage products VP5* and VP8* of HRV strains Wa and ST3. The 
circles represent the epitopes recognized by NMAbs. 
react with either of the two cleavage products of Wa VP4 
were able to bind to ST3-derived VP5* or VP8*. Of the 
two NMAbs tested, HS11 precipitated VP8*, and HS16 
precipitated VP5* (Fig. 1). In five of the variants analyzed, 
the location of the point mutation in gene 4 selected by 
a specific NMAb was shown to lie within the region 
encoding the trypsin cleavage product actually bound by 
the monoclonal (Table 2). 
Operational map of neutralization epitopes on the 
VP4 protein of HRV strains Wa and ST3 
An operational map of homotypic and cross-reactive 
neutralization epitopes on either of the two trypsin cleav- 
age products of VP4 was prepared by performing cross- 
neutralization assays with five pairs of NMAbs and 
NMAb-resistant variants derived form the HRV Wa and 
with four pairs of NMAbs and resistant variants derived 
from the HRV ST3 (Table 3 and Fig. 2). In addition, several 
heterotypic NMAbs that had not been used to select viral 
variants were assayed by neutralization against either or 
both the Wa and the ST3 variants (Table 3). These one- 
way neutralization assays were performed in order to 
determine whether neutralization epitopes on VP4 of the 
HRV strains Wa, ST3, and KU are operationally related. 
The NMAbs used to determine the relationship of the 
VP4s of Wa and ST3 with the VP4 of the serotype P1A 
rotavirus KU were YO-202 and YO-IS3. These NMAbs 
were derived from the serotype P1A strain YO, and recog- 
nize either of the two neutralization domains previously 
identified on KU VP4 by viral variant analysis (Kobayashi 
et al., 1990). 
Both reciprocal and nonreciprocal reactivity patterns 
were found in pairwise combinations. For example, recip- 
rocal reactions were noted between NMAbs 1A10 and 
106 when tested against their variants. Both variants 
were resistant to either NMAb. Nonreciprocal reactions 
were noted between NMAbs HS6 and HS11 when tested 
against their variants. ST3-HS6 was resistant to HS11, 
but ST3-HS11 was neutralized by HS6 (Table 3). 
The operational maps of neutralization epitopes on the 
Wa and ST3 VP4s were constructed by considering as 
overlapping epitopes those involved in either reciprocal 
or nonreciprocal reactivity, as suggested by Yewdell and 
Gerhard (1981) (Fig. 2). All five neutralization epitopes 
studied on Wa VP4 were found to be operationally over- 
lapping, constituting a single large neutralization domain 
on VP5* (Fig. 2). Epitopes 1E4 and 2Ol l  were indistin- 
guishable. On the other hand, the four epitopes studied 
on HRV ST3 were found to constitute two operationally 
nonoverlapping neutralization domains that are located 
on either VP8* (epitopes HS6 and HS11) or VP5* (epi- 
topes HS7 and HS16) (Fig. 2). 
Six cross-reactive NMAbs were assayed by one-way 
neutralization tests. Two were tested against all Wa and 
ST3 variants (YO-1 $3 and YO-202), one against Wa vari- 
ants (HS7), and three against ST3 variants (1E4, 2011, 
and 2A3) (Table 3). One or more Wa or ST3 variants 
selected with anti-VP5* NMAbs were resistant to NMAb 
YO-IS3; hence, the neutralization domains described in 
this study on VPS* of either Wa or ST3 are operationally 
related to the large neutralization domain recognized by 
NMAb YO-IS3 on the VP4 protein of HRV KU (Kobayashi 
et al., 1990). In addition, all Wa and ST3 variants were 
neutralized by NMAb YO-202 to the same titer as the 
parental strains, suggesting that the neutralization do- 
mains on Wa and ST3 VP4 are not operationally related 
to the neutralization domain recognized solely by NMAb 
YO-202 on KU VP4 (Kobayashi et aL, 1990). Neither of 
the two ST3 variants selected with anti-VP8* NMAbs 
(ST3-HS6 and ST3-HS11) were resistant to any of the 
heterotypic or homotypic VP5*-specific NMAbs tested, 
suggesting that the neutralization domain on VP8* of HRV 
ST3 is not operationally related to neutralization domains 
on VP5* of HRV strains Wa, KU, or ST3. 
DISCUSSION 
We have identified four neutralization sites on the VP4 
protein of HRVs, at amino acids 72,217,385, and 458, that 
are either homotypic or associated with limited cross- 
reactivity. Homotypic neutralization sites had been pre- 
viously identified at amino acids 385 and 392 of HRVs, 
although the original description of their reactivity re- 
ferred to G rather than P serotypes (Kobayashi et al., 
1990; Taniguchi etaL,  1988). Amino acid 385 was identi- 
fied on a KU variant selected with the serotype P1A- 
specific NMAb KU-12H (Kobayashi et aL, 1990), and 
amino acid 392 on a DS1 variant selected with the sere- 
type P1 B-specific NMAb $2-2F2 (Taniguchi et al., 1988). 
In addition, amino acid 392 has been identified by us 
and others as important for neutralization by heterotypic 
NMAbs in human and animal rotavirus strains (Kobaya- 
shi et aL, 1990; Taniguchi et al., 1988; Mackow et aL, 
1988). The findings in this study indicate that both homo- 
typic and heterotypic epitopes can be identified on VP8* 
as well as VP5*. Which regions are best able to stimulate 
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heterotypic immunity after natural infection or vaccination 
remains to be determined. 
The functional overlapping between the two epitopes 
that constitute the neutralization domain on ST3 VPS*, in 
spite of their distant location in the amino acid sequence 
(from position 72 to 217), suggests that either the amino 
acid change selected by one NMAb causes an allosteric 
effect which affects the binding of the second NMAb or 
the sites recognized by these monoclonals are conforma- 
ti0nally close. Two lines of evidence favor the second 
hypothesis= (i) it has been implicated that some tertiary 
structure is necessary for binding of NMAbs, since mono- 
cl0nals directed to RRV VPS* select mutations that are 
widely distributed (from amino acids 87 to 188), but they 
all require the same large polypeptide for binding (amino 
acids 55-222) (Mackow et aL, 1990), and (ii) each of 
these VPS* NMAbs competes with others for VP4 bind- 
ing, suggesting that these monoclonals bind to adajcent 
domains of VPS* (Shaw et aL, 1987). 
The neutralization domains on VP5* of HRVs Wa and 
ST3 described in this study, as well as a neutralization 
domain on VP5* of RRV (Mackow etaL, 1988), are opera- 
tionally related to the large neutralization domain on HRV 
KU. This operational relationship is not surprising since 
some of the amino acids that define this domain (amino 
acids 385 and 392) are located within the putative fusion 
region on group A rotaviruses, which spans amino acids 
384 to 401 of RRV VP4 (Mackow et aL, 1988). It is tempting 
to speculate that NMAbs directed to this domain would 
neutralize by interfering with the presumed function of 
the fusion region, i.e., the productive internalization of 
virions to the host cell. 
The ratio of NMAbs directed toward VPS* and VP5* 
that have been isolated from human compared to animal 
r0taviruses is different. Among HRVs, five NMAbs have 
been described that map to VPS* and 25 to VP5* (Kitaoka 
eta/., 1986; Kobayashi eta/., 1990; Kobayashi etaL, 1991; 
Padilla-Noriega et aL, 1993; Taniguchi et aL, 1988). 
Among animal rotaviruses 20 NMAbs have been de- 
scribed that map to VPS* and three to VP5* (Liprandi et 
al., 1991; Mackow et aL, 1988; Zhou et aL, 1994). It is 
unclear why more NMAbs directed at animal rotaviruses 
map to VPS*, while the reverse is true for N MAbs directed 
at human retavirus VP4s. This difference could be the 
result of differences in screening strategies or the reflec- 
ti0n of a more fundamental biologic difference. In addi- 
tion, the neutralization sites on VPS* of the HRV ST3 (at 
positions 72 and 217) are different and are located either 
upstream or downstream of the corresponding amino 
acids identified in animal rotavirus strains (at positions 
87,88, 89, 100, 114, 148, 150, and 188). These differences 
may be either the result of insufficient sample testing or 
from a significant biologic difference between VPS*s of 
human and animal rotaviruses. It is not currently known 
which parts of VP4 represent primary targets of protective 
immunity after natural infection as opposed to hyperim- 
munization. 
it has been suggested that VPS* from animal and hu- 
man rotaviruses have different functions in the early 
steps of host cell infection (Mendez et al., 1993). Among 
animal rotaviruses VPS* has been identified as the viral 
hemagglutinin (Fiore eta/., 1991) and the target of neu- 
tralizing antibodies that inhibit binding of virions to host 
cells (Ruggeri and Greenberg, 1991). in addition, binding 
of animal rotaviruses to erythrocytes and to host ceils 
is dependent on the presence of sialic acid-containing 
receptors, since treatment of cells with sialidases inter- 
feres with such binding (Fukudome et al., 1989). On the 
other hand, although HRVs VPS* is clearly a target of 
neutralizing antibodies, HRVs do not hemagglutinate, 
and infection of cells by HRVs is not dependent on the 
presence of ~ialic acids on the cell surface. The two anti- 
VPS* NMAbs described in this study should be useful 
tools in defining the role of HRV VPS* in the early steps 
of host cell infection. 
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